| Literature DB >> 28732526 |
Tristan Pascart1,2,3, Agathe Grandjean4, Laurène Norberciak5, Vincent Ducoulombier4, Marguerite Motte4, Hélène Luraschi4, Marie Vandecandelaere4, Catherine Godart4, Eric Houvenagel4, Nasser Namane6, Jean-François Budzik6,7.
Abstract
BACKGROUND: Ultrasonography (US) and dual-energy computed tomography (DECT) can assess urate burden in gout. The objective of this study was to compare the quantification of urate deposition provided by US to the one provided by DECT.Entities:
Keywords: Double contour; Dual-energy computed tomography; Gout; Tophus; Ultrasonography
Mesh:
Substances:
Year: 2017 PMID: 28732526 PMCID: PMC5521183 DOI: 10.1186/s13075-017-1381-2
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Patients’ characteristics
| Characteristic | Value in study sample |
|---|---|
| Number of patients | 64 |
| Male | 54 (84.4%) |
| Age (years) | 65.4 ± 14.1 |
| Body mass index | 28.5 ± 4.1 |
| High blood pressure | 34 (53.1%) |
| Coronary heart disease | 12 (18.8%) |
| Peripheral arterial disease | 3 (4.7%) |
| Stroke | 7 (10.9%) |
| Dyslipidaemia | 34 (53.1%) |
| Diabetes mellitus | 17 (26.6%) |
| Chronic sleep apnoea | 9 (14.1%) |
| Psoriasis | 6 (9.4%) |
| Ongoing diuretic treatment | 15 (23.4%) |
| History of renal stones | 11 (17.2%) |
| Familial history of gout | 14 (21.9%) |
| eGFR (CKD-EPI/MDRD) | 75.6 ± 25.6 |
| CKD 3 or worse (clearance <60 ml/min) | 16 (25.0%) |
| Daily alcohol consumption (g) | 14.5 ± 22.7 |
| Excessive sweetened beverages | 8 (12.5%) |
| Excessive purine-rich foods | 17 (26.6%) |
| 2015 ACR/EULAR diagnosis score | 12.8 ± 2.4 |
| Crystal-proven gout | 11 (17.2%) |
| Clinical tophi | 21 (32.8%) |
| Gout duration (years) | 12.8 ± 12.3 |
| Number of flares per year | 4 ± 6 |
| Ongoing urate-lowering therapy ( | 43 (67.2%) |
| Urate-lowering therapy | |
| Febuxostat | 17 (39.5%) |
| Allopurinol | 24 (55.8%) |
| Benzbromarone | 1 (2.3%) |
| Probenecid | 1 (2.3%) |
| Serum uric acid level (mg/dl) | 7.36 ± 2.55 |
Quantitative variables are expressed as mean ± standard deviation, and qualitative variables as number (percentage). eGFR estimated glomerular filtration rate, CKD chronic kidney disease, MDRD modification of diet in renal disease, ACR American College of Rheumatology, EULAR European League Against Rheumatism
Fig. 1a Tophus of the first metatarsophalangeal joint assessed by ultrasonography (US) (top) and dual-energy computed tomography (DECT) (bottom). b US double contour sign. c DECT scans of the knees. d DECT scans of the feet
Ultrasonographic identification of tophi and the double contour (DC) sign
| Ultrasonic features | Prevalence | Missing values ( |
|---|---|---|
| Detection of at least one US tophus | 34 (53.1%) | |
| Localisation of the largest US tophus | ||
| Right MTP | 17 (50%) | |
| Left MTP | 9 (26.5%) | |
| Right ankle | 0 (0%) | |
| Left ankle | 1 (2.9%) | |
| Right knee | 1 (2.9%) | |
| Left knee | 6 (17.6%) | |
| US tophus volume (cm3) | 2.5 ± 6.5 | |
| At least one joint with positive DC sign | 61 (95.3%) | |
| Localisation of DC signs | ||
| Right MTP | 48 (81.3%) | 2 |
| Left MTP | 51 (86.4%) | 2 |
| Right TC | 16 (26.7%) | 1 |
| Left TC | 18 (30%) | 1 |
| Right FP | 16 (25%) | |
| Left FP | 14 (21.9%) | |
Quantitative variables are expressed as mean ± standard deviation, and qualitative variables as number (percentage). MTP metatarsophalangeal joint, TC talo-crural joint, FP femoro-patellar joint
Dual-energy computed tomography (DECT) volume measurements of urate deposits and tophi expressed in cm3
| DECT features | Total population | Patients with US tophi | Patients without US tophi |
|---|---|---|---|
| (N = 64) | (N = 34) | (N = 30) | |
| Volume of urate deposition of the knees | 7.3 ± 31.1 | 12.5 ± 40.6 | 0.4 ± 0.6 |
| Volume of urate deposition of the feet | 5.6 ± 17.1 | 9.7 ± 22.4 | 0.7 ± 0.6 |
| Volume of overall urate deposition | 13.6 ± 48.6 | 22.6 ± 62.5 | 1.1 ± 1.2 |
| Volume of the index tophus | N/A | 1.3 ± 3.2 | N/A |
| Volume of the largest urate deposit seen by DECT | 1.4 ± 5 | 2.6 ± 6.7 | 0.1 ± 0.1 |
Variables are expressed as mean ± standard deviation. N/A not applicable
Fig. 2Dual energy computed tomography (DECT) and ultrasonography (US) provide different quantification of urate deposition. a Comparison of each individual tophus volume as measured by DECT (triangles) and US (squares). b Ratio of the volume measured with DECT and US for each individual tophus. c Volume of overall urate deposition measured by DECT according to the number of joints presenting with the US double contour (DC) sign
Identification of factors influencing assessment of volumes of overall deposition by dual-energy computed tomography (DECT)
| Factors tested in the model | Association between the factor and volume of deposits assessed by DECT | β regression coefficient |
|
|---|---|---|---|
| Glomerular filtration rate | Yes | -0.024 | 0.008 |
| Gout duration | Yes | 0.041 | 0.03 |
| Body mass index | No | ||
| Number of flares over the last year | No | ||
| Gender | No | ||
| Serum uric acid level | No | ||
| Daily alcohol consumption | Yes | 0.02 | 0.03 |
| Urate lowering therapy duration | No | ||
| Diuretic use | No |
P values <0.05 indicate significant association